ANGLE reports positive findings of its technology in breast cancer study

By Giles Gwinnett

4 October 2023

Share

The Business Magazine article image for: ANGLE reports positive findings of its technology in breast cancer study

Guildford head-quartered diagnostic firm ANGLE plc said a new study had shown its cell harvesting technology could improve treatment options for breast cancer patients.

Researchers at a German university used the company's Parsortix system for the isolation and harvest of disseminated tumour cells (DTCs) from bone marrow samples in 360 breast cancer patients and compared the results to the standard lab method.

The study, published in the International Journal of Molecular Sciences, found that ANGLE's Parsortix system was "easier" to use and yielded "significantly" higher numbers of such cells compared to the standard method.

DTCs have left the primary cancer tumour and travelled in the blood to a distant organ - in this case bone marrow - where they can remain dormant before being released into the blood at a later date. It is thought that this is the most likely cause of relapse for patients who have been in prolonged remission.

A third of breast cancer patients already have DTCs present in the bone marrow at the time of diagnosis and these people, as well as those with persistent DTCs, have "significantly worse" clinical outcomes than those without DTCs.

ANGLE said the ability to evaluate markers on DTCs may enable clinicians to "optimise targeted therapy and reduce the risk of relapse".

ANGLE's chief scientific officer Karen Miller said: "We are pleased to share the peer-reviewed publication by the University of Tübingen that demonstrates consistently high performance of the Parsortix system for the harvest of DTCs as opposed to CTCs.

"This is the second study centre to demonstrate successful enrichment and harvest of DTCs from bone marrow aspirate highlighting a range of additional potential uses of the Parsortix system in clinical practice."

ANGLE's innovative circulating tumour cell (CTC) diagnostic solutions can be used in research, drug development and clinical oncology and use a simple blood sample.

Visit Hampshire Biz News for bright, upbeat and positive business news from the county

By Giles Gwinnett

Giles Gwinnett is a writer at The Business Magazine. He has been a journalist for more than 20 years and covered a vast array of topics at a range of media settings - in print and online. After his NCTJ newspaper training, he became a reporter in Hampshire before moving to a news agency in Gloucestershire. In recent years, he has been covering the financial markets along with company news for an investor-focused web portal. His many interests include politics, energy and the environment. He lives in Dorset.